May 12, 2026 ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Apr 27, 2026 Targeting underlying causes of neurodegenerative diseases | 2026 Bloom Burton & Co. Healthcare Investor Conference
Mar 25, 2026 ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Mar 18, 2026 ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Feb 4, 2026 ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dec 18, 2025 ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Dec 10, 2025 ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk